solifenacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
muscarinic receptors antagonists 2457 242478-37-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • YM-67905
  • YM-905
  • solifenacin
  • solifenacin succinate
  • vesicare
A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.
  • Molecular weight: 362.47
  • Formula: C23H26N2O2
  • CLOGP: 4.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 32.78
  • ALOGS: -3.70
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 12.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.30 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 8.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 52 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PRKDC,TGFBR1 20
kinase-selectivity-class AXL,GRK2 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 2004 FDA ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 191.19 11.89 451 28320 481359 90118317
Multiple sclerosis relapse 162.66 11.89 134 28637 52171 90547505
Urinary incontinence 133.31 11.89 104 28667 37462 90562214
Urinary retention 126.42 11.89 101 28670 37643 90562033
Urinary tract infection 124.10 11.89 289 28482 305343 90294333
Dry mouth 120.05 11.89 212 28559 183847 90415829
Vision blurred 102.02 11.89 149 28622 110144 90489532
Maternal exposure during pregnancy 85.23 11.89 8 28763 360055 90239621
Synovitis 84.65 11.89 5 28766 329747 90269929
Dementia 82.35 11.89 65 28706 23796 90575880
Hand deformity 80.89 11.89 3 28768 296359 90303317
Acute kidney injury 80.58 11.89 254 28517 320133 90279543
Glossodynia 73.93 11.89 8 28763 321771 90277905
Constipation 66.57 11.89 218 28553 280177 90319499
Residual urine volume increased 64.35 11.89 13 28758 94 90599582
Infusion related reaction 62.59 11.89 27 28744 416753 90182923
Pericarditis 61.33 11.89 7 28764 270144 90329532
Multiple sclerosis 60 11.89 58 28713 27782 90571894
Drug intolerance 59.67 11.89 34 28737 447557 90152119
Contraindicated product administered 58.06 11.89 15 28756 320124 90279552
Joint abscess 54.83 11.89 15 28756 439 90599237
Treatment failure 53.68 11.89 15 28756 303913 90295763
Arteriovenous fistula occlusion 53.01 11.89 14 28757 357 90599319
Gait disturbance 52.63 11.89 192 28579 260304 90339372
Fear of eating 50.90 11.89 14 28757 418 90599258
Lymphocyte count decreased 50.59 11.89 59 28712 34991 90564685
Blue toe syndrome 49.27 11.89 14 28757 472 90599204
Dysuria 48.20 11.89 61 28710 39340 90560336
Hepatic enzyme increased 44.46 11.89 30 28741 360706 90238970
Muscle injury 44.35 11.89 3 28768 176651 90423025
Discomfort 44.07 11.89 16 28755 274319 90325357
Therapeutic product effect decreased 43.23 11.89 17 28754 277554 90322122
Swelling 42.76 11.89 42 28729 419016 90180660
Liver injury 42.52 11.89 3 28768 170564 90429112
Wound 41.83 11.89 22 28749 302958 90296718
Exposure during pregnancy 41.66 11.89 12 28759 238398 90361278
Lower respiratory tract infection 41.32 11.89 14 28757 250645 90349031
Arthropathy 40.58 11.89 34 28737 366208 90233468
Dry throat 39.50 11.89 27 28744 7933 90591743
Joint swelling 39.25 11.89 62 28709 503238 90096438
Hallucination 39.15 11.89 73 28698 65886 90533790
Genital pain 39.11 11.89 13 28758 745 90598931
Cutaneous lupus erythematosus 38.13 11.89 19 28752 3099 90596577
Balance disorder 37.33 11.89 90 28681 96990 90502686
Cerebellar syndrome 37.02 11.89 20 28751 3852 90595824
Blood lactic acid abnormal 36.53 11.89 7 28764 37 90599639
Bladder disorder 36.43 11.89 29 28742 10743 90588933
Dyskinesia 36.16 11.89 51 28720 36483 90563193
Dopamine transporter scintigraphy abnormal 35.80 11.89 8 28763 98 90599578
Hyponatraemia 35.46 11.89 108 28663 133430 90466246
Renal pain 35.41 11.89 25 28746 7734 90591942
Fibromyalgia 34.91 11.89 11 28760 206258 90393418
Hypertonic bladder 34.86 11.89 20 28751 4328 90595348
Feeling abnormal 34.37 11.89 124 28647 167111 90432565
Lip swelling 34.00 11.89 51 28720 38559 90561117
Cutaneous T-cell dyscrasia 33.09 11.89 7 28764 65 90599611
Cognitive disorder 32.99 11.89 70 28701 69337 90530339
Rheumatoid arthritis 32.93 11.89 40 28731 362574 90237102
Joint range of motion decreased 32.10 11.89 3 28768 135640 90464036
Disorientation 31.57 11.89 53 28718 44061 90555615
Loss of consciousness 31.42 11.89 107 28664 140131 90459545
Genital ulceration 31.09 11.89 12 28759 1061 90598615
Nodular rash 30.44 11.89 8 28763 200 90599476
Bladder sphincter atony 29.72 11.89 8 28763 220 90599456
Psoriatic arthropathy 29.46 11.89 18 28753 228317 90371359
Cystitis 29.10 11.89 65 28706 66653 90533023
Bursitis 28.43 11.89 4 28767 131650 90468026
Sinus node dysfunction 28.38 11.89 19 28752 5393 90594283
Dizziness 28.04 11.89 298 28473 588986 90010690
Abdominal discomfort 27.59 11.89 70 28701 477258 90122418
Wrong technique in product usage process 27.13 11.89 66 28705 71505 90528171
Pollakiuria 26.81 11.89 42 28729 32963 90566713
Anal incontinence 26.27 11.89 29 28742 16201 90583475
Sinus arrest 26.02 11.89 13 28758 2133 90597543
Blister 25.48 11.89 26 28745 254972 90344704
Excessive cerumen production 25.46 11.89 9 28762 621 90599055
Night sweats 25.40 11.89 5 28766 128761 90470915
Incontinence 25.27 11.89 26 28745 13409 90586267
Hypersensitivity 25.26 11.89 68 28703 454609 90145067
Gastrointestinal disorder 24.72 11.89 27 28744 256660 90343016
Impaired healing 24.41 11.89 23 28748 234176 90365500
Hallucination, visual 23.99 11.89 33 28738 23059 90576617
Liver function test abnormal 23.84 11.89 51 28720 50794 90548882
Drug interaction 23.34 11.89 159 28612 276294 90323382
Poliomyelitis 23.04 11.89 5 28766 53 90599623
Ophthalmic herpes zoster 22.82 11.89 13 28758 2775 90596901
Oliguria 22.64 11.89 22 28749 10602 90589074
Infection 22.58 11.89 51 28720 362043 90237633
Blood potassium decreased 22.52 11.89 48 28723 47679 90551997
Type 2 diabetes mellitus 22.33 11.89 19 28752 203225 90396451
Stomatitis 22.19 11.89 33 28738 274665 90325011
Labelled drug-drug interaction medication error 21.80 11.89 25 28746 14557 90585119
Pyelonephritis 21.45 11.89 30 28741 21286 90578390
Nocturia 21.41 11.89 21 28750 10234 90589442
Atrial fibrillation 20.92 11.89 91 28680 133520 90466156
Airway remodelling 20.91 11.89 5 28766 84 90599592
Hypotonic urinary bladder 20.90 11.89 4 28767 21 90599655
Cerebral haematoma 19.99 11.89 14 28757 4275 90595401
Micturition urgency 19.81 11.89 21 28750 11212 90588464
Irritable bowel syndrome 19.77 11.89 22 28749 207426 90392250
Lip dry 19.74 11.89 4 28767 100951 90498725
Lower urinary tract symptoms 19.68 11.89 5 28766 109 90599567
T-lymphocyte count increased 19.67 11.89 6 28765 260 90599416
Vertigo 19.03 11.89 57 28714 69754 90529922
Heat stroke 18.91 11.89 8 28763 896 90598780
Skin burning sensation 18.85 11.89 27 28744 19584 90580092
Hypokalaemia 18.80 11.89 87 28684 131029 90468647
Injury 18.73 11.89 21 28750 197328 90402348
Product use issue 18.57 11.89 49 28722 329870 90269806
Oscillopsia 18.49 11.89 5 28766 140 90599536
Colitis ischaemic 18.18 11.89 21 28750 12325 90587351
Palatal swelling 18.12 11.89 5 28766 151 90599525
Torsade de pointes 17.77 11.89 23 28748 15159 90584517
Hypercholesterolaemia 17.76 11.89 5 28766 100887 90498789
Central nervous system lesion 17.47 11.89 20 28751 11626 90588050
Drug hypersensitivity 17.29 11.89 82 28689 463527 90136149
Confusional state 17.26 11.89 193 28578 386012 90213664
Neurogenic bladder 17.13 11.89 12 28759 3666 90596010
Peripheral venous disease 17.10 11.89 3 28768 83918 90515758
Arthritis bacterial 16.97 11.89 16 28755 7429 90592247
Upper gastrointestinal haemorrhage 16.97 11.89 28 28743 22948 90576728
Renal tubular necrosis 16.96 11.89 22 28749 14533 90585143
Pain 16.96 11.89 219 28552 996122 89603554
Thalamus haemorrhage 16.88 11.89 7 28764 746 90598930
Intentional product use issue 16.61 11.89 27 28744 216865 90382811
Dry eye 16.46 11.89 48 28723 57883 90541793
Sinusitis 16.39 11.89 55 28716 343033 90256643
Infective myositis 16.31 11.89 4 28767 75 90599601
Sciatica 16.12 11.89 6 28765 101376 90498300
Oral mucosal blistering 16.01 11.89 15 28756 6909 90592767
Toxicity to various agents 16.01 11.89 43 28728 287803 90311873
Malaise 15.99 11.89 268 28503 585718 90013958
Varicose ulceration 15.71 11.89 6 28765 515 90599161
Oral pain 15.57 11.89 33 28738 32650 90567026
Vasculitic rash 15.52 11.89 8 28763 1402 90598274
Head injury 15.45 11.89 32 28739 31156 90568520
Stoma site candida 15.34 11.89 3 28768 18 90599658
Amyloidoma 15.34 11.89 3 28768 18 90599658
Bladder pain 15.30 11.89 10 28761 2727 90596949
Blood viscosity increased 15.27 11.89 5 28766 273 90599403
Alopecia 14.92 11.89 94 28677 494977 90104699
Haematemesis 14.86 11.89 33 28738 33693 90565983
Postictal psychosis 14.72 11.89 4 28767 114 90599562
Poverty of speech 14.46 11.89 5 28766 323 90599353
Small intestinal haemorrhage 14.44 11.89 9 28762 2262 90597414
Subacute hepatic failure 14.28 11.89 4 28767 128 90599548
Lung disorder 14.16 11.89 16 28755 149867 90449809
Syncope 14.12 11.89 81 28690 132582 90467094
Arthralgia 14.02 11.89 169 28602 778353 89821323
Intestinal villi atrophy 14.01 11.89 5 28766 355 90599321
Inflammation 13.89 11.89 22 28749 178570 90421106
Diplopia 13.68 11.89 29 28742 28685 90570991
Renal function test abnormal 13.68 11.89 14 28757 7177 90592499
Urge incontinence 13.66 11.89 7 28764 1212 90598464
Nodal rhythm 13.61 11.89 8 28763 1810 90597866
Visual impairment 13.56 11.89 80 28691 132285 90467391
Somnolence 13.54 11.89 113 28658 208971 90390705
Joint stiffness 13.49 11.89 4 28767 78038 90521638
Disease progression 13.45 11.89 18 28753 156597 90443079
Device colour issue 13.41 11.89 3 28768 37 90599639
Stoma site hypergranulation 13.34 11.89 5 28766 408 90599268
Benign renal neoplasm 13.33 11.89 3 28768 38 90599638
Blood sodium decreased 13.29 11.89 28 28743 27585 90572091
Ill-defined disorder 13.25 11.89 24 28747 184867 90414809
Escherichia urinary tract infection 13.25 11.89 19 28752 13796 90585880
Language disorder 13.17 11.89 9 28762 2643 90597033
Autoimmune disorder 13.14 11.89 4 28767 76740 90522936
Muscular weakness 13.01 11.89 111 28660 206555 90393121
Anticholinergic syndrome 12.89 11.89 9 28762 2734 90596942
Wound infection 12.89 11.89 9 28762 106393 90493283
Antipsychotic drug level above therapeutic 12.82 11.89 7 28764 1377 90598299
Bladder spasm 12.80 11.89 8 28763 2022 90597654
Stoma site pain 12.66 11.89 7 28764 1410 90598266
Hyperthermia 12.64 11.89 16 28755 10319 90589357
Dysgraphia 12.63 11.89 10 28761 3673 90596003
Ligament sprain 12.45 11.89 19 28752 14580 90585096
Disturbance in attention 12.40 11.89 38 28733 47071 90552605
Drug ineffective 12.39 11.89 340 28431 1383958 89215718
Paraparesis 12.34 11.89 9 28762 2929 90596747
Therapeutic product effect incomplete 12.33 11.89 27 28744 193869 90405807
Hereditary angioedema with C1 esterase inhibitor deficiency 12.30 11.89 3 28768 55 90599621
Tremor 12.26 11.89 87 28684 153086 90446590
Cerebral ventricular rupture 12.23 11.89 4 28767 218 90599458
Pseudomembranous colitis 12.20 11.89 10 28761 3858 90595818
Back pain 12.18 11.89 154 28617 317021 90282655
Cardiovascular disorder 12.13 11.89 18 28753 13474 90586202
Secondary progressive multiple sclerosis 11.96 11.89 7 28764 1572 90598104

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral hypoperfusion 147.99 14.74 39 13276 1004 42607016
Urinary retention 132.63 14.74 108 13207 42106 42565914
Constipation 89.37 14.74 172 13143 162119 42445901
Confusional state 89.10 14.74 175 13140 167422 42440598
Dry mouth 85.16 14.74 82 13233 39797 42568223
Fall 58.24 14.74 183 13132 234337 42373683
Hallucination 56.11 14.74 79 13236 57428 42550592
Binocular eye movement disorder 56.01 14.74 14 13301 290 42607730
Feeling cold 48.92 14.74 37 13278 12936 42595084
Urinary tract infection 48.26 14.74 100 13215 99184 42508836
Cerebellar stroke 45.76 14.74 14 13301 623 42607397
Urinary incontinence 43.32 14.74 43 13272 21625 42586395
Speech disorder 42.67 14.74 49 13266 29072 42578948
Dysuria 41.70 14.74 50 13265 31046 42576974
Faecaloma 40.64 14.74 25 13290 6245 42601775
Gastrointestinal hypomotility 39.63 14.74 15 13300 1278 42606742
On and off phenomenon 39.42 14.74 20 13295 3447 42604573
Dementia 39.20 14.74 36 13279 16444 42591576
Micturition urgency 38.50 14.74 31 13284 11867 42596153
Duplicate therapy error 36.93 14.74 10 13305 286 42607734
Nocturia 35.92 14.74 30 13285 12082 42595938
Gait disturbance 35.65 14.74 88 13227 97912 42510108
Genital pain 33.20 14.74 12 13303 898 42607122
Radiation inflammation 31.55 14.74 12 13303 1036 42606984
Hyponatraemia 30.65 14.74 85 13230 101377 42506643
Hyporesponsive to stimuli 30.30 14.74 13 13302 1533 42606487
Genital ulceration 29.73 14.74 11 13304 880 42607140
Balance disorder 27.99 14.74 52 13263 47593 42560427
Epilepsy 27.07 14.74 37 13278 26134 42581886
Pulmonary pain 26.80 14.74 12 13303 1566 42606454
Food poisoning 26.15 14.74 14 13301 2692 42605328
Bladder cancer 25.50 14.74 29 13286 17018 42591002
Somnolence 25.29 14.74 99 13216 141006 42467014
Hallucination, visual 23.70 14.74 31 13284 20989 42587031
Pollakiuria 23.55 14.74 32 13283 22473 42585547
Delirium 23.29 14.74 51 13264 52468 42555552
Retrograde ejaculation 23.12 14.74 8 13307 527 42607493
Cognitive disorder 22.24 14.74 39 13276 34133 42573887
Enterocolitis bacterial 21.50 14.74 7 13308 382 42607638
Product name confusion 20.77 14.74 5 13310 88 42607932
Dizziness 20.74 14.74 141 13174 249113 42358907
Malaise 20.72 14.74 125 13190 212031 42395989
Hypertonic bladder 19.38 14.74 11 13304 2370 42605650
Cerebral amyloid angiopathy 19.33 14.74 6 13309 280 42607740
Upper respiratory tract irritation 18.89 14.74 4 13311 38 42607982
Frustration tolerance decreased 18.54 14.74 12 13303 3274 42604746
Polyuria 18.42 14.74 19 13296 9992 42598028
Volvulus 18.30 14.74 10 13305 2003 42606017
Hormone-dependent prostate cancer 18.28 14.74 4 13311 45 42607975
Pneumonia aspiration 18.22 14.74 45 13270 50033 42557987
Completed suicide 18.08 14.74 4 13311 96461 42511559
Bladder discomfort 18.02 14.74 5 13310 157 42607863
Diplopia 17.03 14.74 26 13289 20290 42587730
Haematuria 17.02 14.74 48 13267 57751 42550269
Irritable bowel syndrome 16.87 14.74 13 13302 4668 42603352
Inappropriate antidiuretic hormone secretion 16.52 14.74 23 13292 16518 42591502
Oral pain 16.46 14.74 20 13295 12576 42595444
Incontinence 16.39 14.74 15 13300 6815 42601205
Body temperature decreased 15.85 14.74 21 13294 14392 42593628
Toxicity to various agents 15.56 14.74 30 13285 229106 42378914
Prostatitis 15.54 14.74 14 13301 6234 42601786
Claudication of jaw muscles 15.53 14.74 3 13312 17 42608003
Foetal heart rate disorder 15.40 14.74 4 13311 97 42607923
Gastrointestinal pain 15.34 14.74 12 13303 4403 42603617
Urosepsis 15.17 14.74 21 13294 14999 42593021

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 206.69 11.56 529 34052 602953 109951765
Urinary retention 175.10 11.56 157 34424 69526 110485192
Urinary incontinence 133.11 11.56 115 34466 48472 110506246
Urinary tract infection 129.43 11.56 303 34278 325979 110228739
Multiple sclerosis relapse 125.81 11.56 113 34468 50127 110504591
Dry mouth 87.31 11.56 193 34388 199755 110354963
Confusional state 80.06 11.56 324 34257 468356 110086362
Dementia 78.81 11.56 71 34510 31602 110523116
Constipation 76.60 11.56 266 34315 357520 110197198
Genital pain 76.57 11.56 25 34556 1375 110553343
Vision blurred 75.92 11.56 141 34440 128881 110425837
Dysuria 72.84 11.56 92 34489 60139 110494579
Hallucination 68.86 11.56 118 34463 101314 110453404
Systemic lupus erythematosus 66.78 11.56 3 34578 254335 110300383
Hyponatraemia 65.27 11.56 182 34399 217471 110337247
Acute kidney injury 64.91 11.56 379 34202 635051 109919667
Fear of eating 61.95 11.56 17 34564 511 110554207
Synovitis 61.26 11.56 7 34574 274085 110280633
Genital ulceration 60.83 11.56 23 34558 1952 110552766
Multiple sclerosis 56.94 11.56 54 34527 25644 110529074
Arteriovenous fistula occlusion 56.73 11.56 16 34565 533 110554185
Hand deformity 56.01 11.56 3 34578 218503 110336215
Maternal exposure during pregnancy 55.75 11.56 7 34574 254876 110299842
Residual urine volume increased 52.78 11.56 11 34570 96 110554622
Treatment failure 51.04 11.56 12 34569 277222 110277496
Infusion related reaction 46.55 11.56 31 34550 381131 110173587
Pericarditis 45.60 11.56 7 34574 219107 110335611
Gait disturbance 44.79 11.56 189 34392 278019 110276699
Blue toe syndrome 44.68 11.56 14 34567 674 110554044
Joint abscess 44.42 11.56 14 34567 687 110554031
Fibromyalgia 41.84 11.56 3 34578 170906 110383812
Hypertonic bladder 41.81 11.56 24 34557 5278 110549440
Dyskinesia 40.50 11.56 64 34517 51382 110503336
Hallucination, visual 39.41 11.56 55 34526 39550 110515168
Renal pain 39.21 11.56 29 34552 9788 110544930
Liver function test abnormal 38.86 11.56 74 34507 68876 110485842
Cognitive disorder 38.75 11.56 85 34496 87426 110467292
Balance disorder 38.45 11.56 101 34480 116459 110438259
Glossodynia 38.20 11.56 11 34570 221993 110332725
Folliculitis 38.17 11.56 4 34577 167649 110387069
Food poisoning 37.73 11.56 24 34557 6348 110548370
Cutaneous lupus erythematosus 36.39 11.56 19 34562 3469 110551249
Disorientation 36.37 11.56 73 34508 70598 110484120
Pollakiuria 36.20 11.56 56 34525 44139 110510579
Gastrointestinal hypomotility 36.08 11.56 17 34564 2491 110552227
Blood lactic acid abnormal 35.70 11.56 8 34573 101 110554617
Malaise 35.49 11.56 343 34238 671476 109883242
Dizziness 35.20 11.56 353 34228 697840 109856878
Incontinence 35.04 11.56 34 34547 16601 110538117
Somnolence 34.66 11.56 184 34397 297265 110257453
Faecaloma 34.32 11.56 32 34549 14876 110539842
Cutaneous T-cell dyscrasia 33.40 11.56 7 34574 63 110554655
Duplicate therapy error 33.02 11.56 10 34571 429 110554289
Therapeutic product effect decreased 32.43 11.56 18 34563 244298 110310420
Psoriatic arthropathy 31.63 11.56 11 34570 196750 110357968
Radiation inflammation 31.54 11.56 12 34569 1036 110553682
Drug hypersensitivity 31.28 11.56 59 34522 454031 110100687
Hepatic enzyme increased 30.71 11.56 33 34548 320859 110233859
Toxicity to various agents 29.25 11.56 67 34514 480488 110074230
Cystitis 29.07 11.56 64 34517 65972 110488746
Loss of consciousness 29.00 11.56 130 34451 196176 110358542
Night sweats 28.52 11.56 4 34577 133979 110420739
Cerebellar syndrome 28.32 11.56 20 34561 6282 110548436
Sinus node dysfunction 28.03 11.56 23 34558 9024 110545694
Blood potassium decreased 27.96 11.56 56 34525 54058 110500660
Dry throat 27.61 11.56 23 34558 9215 110545503
Lower urinary tract symptoms 27.53 11.56 9 34572 497 110554221
Bursitis 27.37 11.56 4 34577 129914 110424804
Anal incontinence 27.26 11.56 34 34547 21930 110532788
Off label use 27.03 11.56 320 34261 1499865 109054853
Nodular rash 26.77 11.56 8 34573 328 110554390
Cerebral amyloid angiopathy 26.71 11.56 9 34572 546 110554172
Gastrointestinal pain 26.42 11.56 25 34556 11835 110542883
Oral pain 25.97 11.56 44 34537 37400 110517318
Exposure during pregnancy 25.83 11.56 10 34571 167414 110387304
Lip swelling 25.66 11.56 52 34529 50615 110504103
Volvulus 25.29 11.56 15 34566 3503 110551215
Neurogenic bladder 24.89 11.56 17 34564 5062 110549656
Lymphocyte count decreased 24.66 11.56 55 34526 57188 110497530
Rheumatoid arthritis 24.28 11.56 35 34546 299578 110255140
Swelling 23.82 11.56 46 34535 350995 110203723
Wound 23.68 11.56 23 34558 234414 110320304
Oliguria 23.35 11.56 29 34552 18628 110536090
Liver injury 23.17 11.56 9 34572 150404 110404314
Bladder cancer 22.96 11.56 30 34551 20262 110534456
Discomfort 22.95 11.56 20 34561 214687 110340031
Drug intolerance 22.90 11.56 59 34522 406453 110148265
Poliomyelitis 22.78 11.56 5 34576 57 110554661
Bladder discomfort 22.70 11.56 9 34572 867 110553851
Infection 22.43 11.56 50 34531 362150 110192568
Completed suicide 22.01 11.56 26 34555 242355 110312363
Excessive cerumen production 21.93 11.56 9 34572 949 110553769
Urosepsis 21.22 11.56 36 34545 30639 110524079
Feeling abnormal 21.17 11.56 112 34469 180599 110374119
Joint range of motion decreased 21.02 11.56 6 34575 121826 110432892
Micturition urgency 20.99 11.56 28 34553 19292 110535426
Arthralgia 20.58 11.56 151 34430 779481 109775237
Drug interaction 20.58 11.56 243 34338 499940 110054778
Torsade de pointes 20.45 11.56 30 34551 22570 110532148
Sinus arrest 20.32 11.56 14 34567 4228 110550490
Disease progression 20.27 11.56 28 34553 244006 110310712
T-lymphocyte count increased 20.27 11.56 6 34575 238 110554480
Drug ineffective 20.06 11.56 345 34236 1520195 109034523
Myelosuppression 19.65 11.56 3 34578 94337 110460381
Delirium 19.62 11.56 89 34492 134936 110419782
Injury 19.57 11.56 16 34565 177249 110377469
Joint swelling 19.45 11.56 72 34509 442773 110111945
Contraindicated product administered 19.14 11.56 30 34551 248237 110306481
Lip dry 19.08 11.56 4 34577 100079 110454639
Haematuria 18.84 11.56 63 34518 82942 110471776
Stomatitis 18.69 11.56 35 34546 270207 110284511
Labelled drug-drug interaction medication error 18.46 11.56 33 34548 29269 110525449
Freezing phenomenon 18.43 11.56 11 34570 2598 110552120
Arthropathy 18.37 11.56 39 34542 287483 110267235
Intentional product use issue 18.14 11.56 31 34550 247875 110306843
Impaired healing 17.97 11.56 21 34560 196696 110358022
Hypersensitivity 17.53 11.56 66 34515 403932 110150786
Nocturia 17.51 11.56 24 34557 16966 110537752
Hypertonia 17.37 11.56 17 34564 8389 110546329
Pseudomembranous colitis 17.24 11.56 15 34566 6376 110548342
Retrograde ejaculation 17.19 11.56 6 34575 405 110554313
Hyperkalaemia 17.18 11.56 86 34495 135710 110419008
Enterocolitis bacterial 17.18 11.56 7 34574 724 110553994
Gastrointestinal disorder 17.03 11.56 31 34550 241921 110312797
Hypophagia 16.74 11.56 45 34536 52581 110502137
Atrial fibrillation 16.70 11.56 126 34455 229516 110325202
Nightmare 16.36 11.56 37 34544 38826 110515892
Oral mucosal blistering 16.31 11.56 16 34565 7918 110546800
Product name confusion 16.24 11.56 5 34576 227 110554491
Drug abuse 16.14 11.56 19 34562 177392 110377326
Head injury 15.98 11.56 39 34542 42978 110511740
Electrocardiogram QT prolonged 15.96 11.56 72 34509 108888 110445830
Pain 15.88 11.56 207 34374 954748 109599970
Palatal swelling 15.85 11.56 5 34576 246 110554472
Thalamus haemorrhage 15.78 11.56 9 34572 1955 110552763
Upper respiratory tract irritation 15.75 11.56 5 34576 251 110554467
Anticholinergic syndrome 15.66 11.56 12 34569 4268 110550450
Arthritis bacterial 15.47 11.56 18 34563 10802 110543916
Claudication of jaw muscles 15.36 11.56 4 34577 98 110554620
Pyelonephritis 15.35 11.56 28 34553 25222 110529496
Sinusitis 15.25 11.56 45 34536 296643 110258075
Amyloidoma 15.24 11.56 3 34578 19 110554699
Therapy non-responder 15.24 11.56 16 34565 157291 110397427
Bladder pain 15.22 11.56 10 34571 2795 110551923
Muscular weakness 15.17 11.56 131 34450 248337 110306381
Stoma site candida 15.11 11.56 3 34578 20 110554698
Type 2 diabetes mellitus 15.05 11.56 20 34561 177212 110377506
Bladder disorder 15.05 11.56 18 34563 11119 110543599
Secondary progressive multiple sclerosis 14.82 11.56 8 34573 1561 110553157
Hypercholesterolaemia 14.73 11.56 5 34576 90832 110463886
Renal function test abnormal 14.70 11.56 16 34565 8930 110545788
Lower respiratory tract infection 14.69 11.56 34 34547 243072 110311646
Blister 14.39 11.56 31 34550 227345 110327373
Dehydration 14.36 11.56 142 34439 279369 110275349
Musculoskeletal stiffness 13.98 11.56 43 34538 279779 110274939
Blood viscosity increased 13.92 11.56 5 34576 367 110554351
Neutropenia 13.90 11.56 65 34516 374555 110180163
Pulmonary pain 13.51 11.56 13 34568 6280 110548438
Heat illness 13.37 11.56 6 34575 786 110553932
Speech disorder 13.33 11.56 46 34535 61523 110493195
Cerebral infarction 13.27 11.56 41 34540 51797 110502921
Benign renal neoplasm 13.24 11.56 3 34578 40 110554678
Acute disseminated encephalomyelitis 13.21 11.56 5 34576 425 110554293
On and off phenomenon 13.19 11.56 11 34570 4413 110550305
Oscillopsia 13.19 11.56 5 34576 427 110554291
Vertigo 13.17 11.56 58 34523 86812 110467906
Stoma site pain 13.16 11.56 8 34573 1955 110552763
Drug ineffective for unapproved indication 13.04 11.56 8 34573 102830 110451888
Wound infection 12.95 11.56 7 34574 96458 110458260
Inappropriate antidiuretic hormone secretion 12.90 11.56 31 34550 33820 110520898
Bladder spasm 12.76 11.56 9 34572 2823 110551895
Cerebral haemorrhage 12.75 11.56 47 34534 64921 110489797
Cerebral ventricular rupture 12.73 11.56 5 34576 470 110554248
Blood cholesterol increased 12.71 11.56 24 34557 184761 110369957
Proctitis ulcerative 12.70 11.56 5 34576 473 110554245
Escherichia urinary tract infection 12.57 11.56 20 34561 16142 110538576
Cystitis interstitial 12.51 11.56 7 34574 1467 110553251
International normalised ratio increased 12.46 11.56 57 34524 86715 110468003
Hormone-dependent prostate cancer 12.43 11.56 4 34577 210 110554508
Blood sodium decreased 12.42 11.56 33 34548 38286 110516432
Prostatitis 12.41 11.56 11 34570 4790 110549928
Lethargy 12.36 11.56 60 34521 93516 110461202
Device colour issue 12.34 11.56 3 34578 55 110554663
Hereditary angioedema with C1 esterase inhibitor deficiency 12.24 11.56 3 34578 57 110554661
Parkinson's disease 12.22 11.56 7 34574 1532 110553186
Infective myositis 12.16 11.56 4 34577 225 110554493
Vasculitic rash 12.13 11.56 8 34573 2249 110552469
Haematemesis 11.80 11.56 43 34538 59065 110495653
Intestinal villi atrophy 11.79 11.56 5 34576 572 110554146
Paralysis 11.72 11.56 19 34562 15581 110539137
Dementia with Lewy bodies 11.68 11.56 6 34575 1060 110553658
Poverty of speech 11.59 11.56 5 34576 596 110554122

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD08 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
ATC G04CA53 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000125 Cholinergic Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D064804 Urological Agents
FDA EPC N0000175700 Cholinergic Muscarinic Antagonist
CHEBI has role CHEBI:35846 renal agent

Related Drugs by ATC class:

G04BD Drugs for urinary frequency and incontinence 13 drugs
darifenacinemeproniumfesoterodineflavoxateimidafenacinmeladrazinemirabegronoxybutyninpropiverineterodilinetolterodinetrospium show all 13 →
G04CA Alpha-adrenoreceptor antagonists 8 drugs
alfuzosindoxazosindutasteridefinasteridesilodosintadalafiltamsulosinterazosin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Increased Urinary Frequency indication
Torsades de pointes contraindication 31722008
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Prolonged QT interval contraindication 111975006
Gastrointestinal obstruction contraindication 126765001
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Retention of urine contraindication 267064002
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastrointestinal hypomotility contraindication 421807004
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST IC50 6.88 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST IC50 6.24 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M5 GPCR ANTAGONIST Ki 7.20 IUPHAR
Muscarinic acetylcholine receptor M1 GPCR IC50 7.20 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR ANTAGONIST Ki 6.80 IUPHAR
Muscarinic acetylcholine receptor M2 GPCR Ki 6.92 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 8 CHEMBL

External reference:

IDSource
4024390 VUID
N0000022393 NUI
D01269 KEGG_DRUG
242478-38-2 SECONDARY_CAS_RN
4021510 VANDF
4024390 VANDF
C1099677 UMLSCUI
CHEBI:135530 CHEBI
CHEMBL1734 ChEMBL_ID
CHEMBL1200803 ChEMBL_ID
DB01591 DRUGBANK_ID
D000069464 MESH_DESCRIPTOR_UI
154059 PUBCHEM_CID
7483 IUPHAR_LIGAND_ID
8155 INN_ID
A8910SQJ1U UNII
322167 RXNORM
19082 MMSL
256920 MMSL
63797 MMSL
d05413 MMSL
008712 NDDF
008713 NDDF
407030007 SNOMEDCT_US
407031006 SNOMEDCT_US
426324001 SNOMEDCT_US
A8910SQJ1U INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 0591-3795 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 0591-3796 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
solifenacin succinate Human Prescription Drug Label 1 27241-037 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
solifenacin succinate Human Prescription Drug Label 1 27241-038 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 29300-328 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 29300-329 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 31722-027 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
solifenacin succinate HUMAN PRESCRIPTION DRUG LABEL 1 31722-028 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
solifenacin succinate Human Prescription Drug Label 1 33342-148 TABLET, COATED 5 mg ORAL ANDA 27 sections
solifenacin succinate Human Prescription Drug Label 1 33342-149 TABLET, COATED 10 mg ORAL ANDA 27 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 35561-285 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 35561-286 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 42291-739 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 42291-740 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
Solifenacin Succinate Human Prescription Drug Label 1 46708-192 TABLET, COATED 5 mg ORAL ANDA 27 sections
Solifenacin Succinate Human Prescription Drug Label 1 46708-193 TABLET, COATED 10 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 50228-427 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 50228-428 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 51248-150 TABLET, FILM COATED 5 mg ORAL NDA 26 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 51248-151 TABLET, FILM COATED 10 mg ORAL NDA 26 sections
VESIcareLS HUMAN PRESCRIPTION DRUG LABEL 1 51248-250 SUSPENSION 1 mg ORAL NDA 26 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 51407-471 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 51407-472 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 54868-4705 TABLET, FILM COATED 10 mg ORAL NDA 26 sections
VESIcare HUMAN PRESCRIPTION DRUG LABEL 1 54868-5398 TABLET, FILM COATED 5 mg ORAL NDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4702 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Solifenacin Succinate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4703 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Solifenacin Succinate Human Prescription Drug Label 1 62332-192 TABLET, COATED 5 mg ORAL ANDA 27 sections
Solifenacin Succinate Human Prescription Drug Label 1 62332-193 TABLET, COATED 10 mg ORAL ANDA 27 sections
SOLIFENACIN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 63629-8532 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections